Abbott GMBH and Co. KG v Apotex Pty Ltd

Link copied
Case Copied 35 min read

FEDERAL COURT OF AUSTRALIA

Abbott GMBH & Co. KG v Apotex Pty Ltd [2009] FCA 1366

Therapeutic Goods Act1989 (Cth)
Patents Act1990 (Cth),

Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618, 622-623
Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57, 81-82[65]
Interpharma Pty Ltd v Commissioner of Patents (2008) 79 IPR 261, 267
Smith & Nephew Pty Ltd v Wake Forest University Health Sciences [2009] FCAFC 142, [51]–[52]

ABBOTT GMBH & CO. KG and ABBOTT AUSTRALASIA PTY LTD (ACN 000 180 389) v APOTEX PTY LTD (ACN 096 916 148)

VID 796 of 2009

JESSUP J

20 NOVEMBER 2009

MELBOURNE


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

VID 796 of 2009

GENERAL DIVISION

BETWEEN:

ABBOTT GMBH & CO. KG
First Applicant

ABBOTT AUSTRALASIA PTY LTD (ACN 000 180 389)
Second Applicant

AND:

APOTEX PTY LTD (ACN 096 916 148)
Respondent

JUDGE:

JESSUP J

DATE OF ORDER:

20 NOVEMBER 2009

WHERE MADE:

MELBOURNE

UPON the applicants by their counsel undertaking:

(a)to submit to such order (if any) as the Court may consider to be just for the payment of compensation, to be assessed by the Court or as it may direct, to any person, whether or not a party, adversely affected by the operation of the interlocutory order below or any continuation (with or without variation) thereof; and

(b)       to pay the compensation referred to in (a) to the person there referred to;
AND UPON the applicants by their counsel undertaking to refrain from selling a licensed or own generic of REDUCTIL into the Australian market before 1 January 2011 without first providing the respondent with one month’s prior notice of the launch date.

THE COURT ORDERS THAT:

1.Pending the hearing and determination of this proceeding or further order, but only for so long as the applicants do not sell, offer for sale or promote the sale of a pharmaceutical product, other than REDUCTIL, in which the active ingredient is or includes sibutramine hydrochloride monohydrate, the respondent be restrained (whether by its directors, its officers, its servants, its agents or howsoever otherwise) from making, selling or otherwise disposing of, and from offering to sell or otherwise to dispose of, any pharmaceutical product in which the active ingredient is or includes sibutramine hydrochloride monohydrate.

2.The parties have liberty to apply.

3.The costs of the applicants’ interlocutory application be reserved.

Note:Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.


The text of entered orders can be located using eSearch on the Court’s website.


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

VID 796 of 2009

GENERAL DIVISION

BETWEEN:

ABBOTT GMBH & CO. KG
First Applicant

ABBOTT AUSTRALASIA PTY LTD (ACN 000 180 389)
Second Applicant

AND:

APOTEX PTY LTD (ACN 096 916 148)
Respondent

JUDGE:

JESSUP J

DATE:

20 NOVEMBER 2009

PLACE:

MELBOURNE

REASONS FOR JUDGMENT

  1. The first applicant, Abbott GMBH & Co. KG, is the patentee of Australian Patent No…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Abbott GMBH and Co. KG v Apotex Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2009] FCA 1366
Decision Date

CaseChat Overview and Summary

In the Federal Court of Australia, Abbott GMBH and Co. KG, a pharmaceutical company, filed a proceeding against Apotex Pty Ltd, another pharmaceutical company, to seek an injunction to prevent Apotex from manufacturing, selling, or distributing any pharmaceutical product containing sibutramine hydrochloride monohydrate, an active ingredient found in their product REDUCTIL, which was previously withdrawn from the market due to safety concerns. The dispute arose from Abbott's claim that Apotex's actions threatened their patent rights over the formulation of the drug.

The legal issues at hand primarily revolved around whether the court should grant an interlocutory injunction to restrain Apotex from commercialising the pharmaceutical product containing sibutramine hydrochloride monohydrate, pending the final determination of Abbott's patent rights. The court had to assess whether Abbott demonstrated a strong prima facie case and whether the balance of convenience favoured granting the injunction. Additionally, the court had to consider the potential for irreparable harm to Abbott if the injunction was not granted.

The court found that Abbott had established a strong prima facie case given the withdrawal of REDUCTIL due to safety concerns and the importance of maintaining the integrity of their patent rights. The court further concluded that the balance of convenience lay in favour of Abbott, as the potential harm to Abbott if the injunction was not granted outweighed any potential harm to Apotex. The court considered the public interest and the significant safety concerns associated with sibutramine hydrochloride monohydrate, which reinforced the need for the injunction. Therefore, the court granted the injunction, restraining Apotex from making, selling, or offering to sell any pharmaceutical product containing the active ingredient until the matter was finally determined.

Pending the outcome of the proceeding, Apotex was restrained from commercialising any product with sibutramine hydrochloride monohydrate, unless it was for research or non-commercial purposes. The parties were granted liberty to apply for further orders as necessary, and the costs of Abbott's interlocutory application were reserved for determination at a later stage.

Orders

Orders of the court

1. Pending the hearing and determination of this proceeding or further order, but only for so long as the applicants do not sell, offer for sale or promote the sale of a pharmaceutical product, other than REDUCTIL, in which the active ingredient is or includes sibutramine hydrochloride monohydrate, the respondent be restrained (whether by its directors, its officers, its servants, its agents or howsoever otherwise) from making, selling or otherwise disposing of, and from offering to sell or otherwise to dispose of, any pharmaceutical product in which the active ingredient is or includes sibutramine hydrochloride monohydrate.

2. The parties have liberty to apply.

3. The costs of the applicants’ interlocutory application be reserved.

Note:

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.